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Abstract: It has been recognized for decades that proteins, which are encoded by our 
genome and produced via transcription and translation steps, are building blocks that play 
vital roles in almost all biological processes. Mutations identified in many protein-coding 
genes are linked to various human diseases. However, this “protein-centered” dogma has 
been challenged in recent years with the discovery that the majority of our genome is 
“non-coding” yet transcribed. Non-coding RNA has become the focus of “next generation” 
biology. Here, we review the emerging field of non-coding RNAs, including microRNAs 
(miRNAs) and long non-coding RNAs (lncRNAs), and their role in cardiovascular function 
and disease. 
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1. Introduction 
When the human genome project was completed, it was surprising that only about 20,000 to 25,000 
protein-coding genes exist in our species, with less than 2% of the human genome used for coding 
proteins. What are the functions of non-coding sequences, which make up more than 98% of our 
genome? The answers are now emerging with the recognition that the majority of the genome is actively 
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transcribed to produce thousands of non-coding transcripts, including microRNAs (miRNAs) and long 
non-coding RNAs (lncRNAs), in many cell types and tissues. miRNAs are a class of small non-coding 
RNAs (~22 nucleotides) and were first discovered in C. elegans two decades ago. More than  
2,000 miRNAs have been found in humans, and many of them are evolutionarily conserved. By 
imperfect base pairing with target mRNAs in a sequence dependent manner, miRNAs repress gene 
expression by degrading target mRNAs and/or inhibiting their translation. Roles for miRNAs have been 
demonstrated in the regulation of a broad range of biological activities and diseases [1]. More recently, 
thousands of lncRNAs, which are transcribed non-coding RNAs greater than 200 nucleotides, were 
discovered and implicated in a variety of biological processes [2,3]. Clearly, investigating and understanding 
of how miRNAs and lncRNAs regulate gene expression during cardiovascular development and 
function will greatly facilitate therapeutic treatment of cardiovascular disease. Here, we briefly review 
the function of miRNAs and lncRNAs in the cardiovascular system and related human disorders. 
2. miRNAs in Cardiac Development 
Global disruption of the expression and maturation of all miRNAs in the heart is the first step to 
understand the function of miRNAs in cardiac development and physiology. Dicer, an RNase III 
endoribonuclease, is a critical enzyme for the maturation of most miRNAs. Conventional deletion of 
Dicer causes early embryonic lethality in mice, demonstrating the critical role of miRNAs in animal 
development [4]. Disrupting miRNA expression in early embryonic hearts using Nkx2.5-Cre mediated 
Dicer mutation leads to improperly compacted ventricular myocardium in mutant embryos [5], further 
indicating that miRNAs are indispensible for cardiogenesis. Similarly, α-MHC-Cre-mediated conditional 
deletion of Dicer causes postnatal lethality due to dilated cardiomyopathy and heart failure [6]. These 
studies suggest that many miRNAs play crucial roles in cardiac development and physiological function. 
miR-1 is tissue-specifically expressed in the heart and skeletal muscle, and genetic deletion of both 
miR-1-1 and miR-1-2 indicated that miR-1 is required for cardiomorphogenesis and the expression of 
many cardiac contractile proteins [7,8]. 
3. Cardiac Regeneration Regulated by miRNAs 
Mammalian adult cardiomyocytes are terminally differentiated cells that exit the cell cycle. Lack of 
regenerative ability of adult hearts is one of the major causes of cardiomyopathy. A recent report 
identified about 40 miRNAs that strongly enhanced cell proliferation in neonatal mouse and rat 
cardiomyocytes. Two of these miRNAs, miR-590 and miR-199a, were further demonstrated to induce 
cardiomyocyte proliferation both in vitro and in vivo [9]. It remains to be determined which molecular 
target(s) mediate the function of these miRNAs in cardiomyocyte proliferation. Using both gain- and 
loss-of function approaches in transgenic and knockout mouse models, we demonstrated that the 
miR-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation. More specifically, we 
identified miR-19a/b as the major contributors among the miR-17-92 cluster to the regulation of the 
cardiomyocyte proliferation [10]. Mechanistically, we identified Pten as one of the miR-19a/19b targets 
which participate in the regulation of cardiomyocyte proliferation. These studies demonstrate that 
miRNAs are key regulators of cardiomyocyte proliferation and heart regeneration, suggesting their 
significant therapeutic potential to treat cardiac-degeneration associated heart disease. Cells 2014, 3  885 
 
 
In rodent hearts, neonatal cardiomyocytes can still proliferate, leading to the regeneration potential  
in newborn hearts. However, proliferation potential is gradually lost by postnatal day 7 (P7) and 
cardiomyocytes exit the cell cycle by then. As a result, hearts beyond P7 lost their potential to regenerate 
in response to stress or injury. Through profiling and comparing miRNA expression between P1 and P10 
rat cardiomyocytes, members of the miR-15 family, including miR-195, miR-15a, miR-15b, miR-16, 
and miR-497, were identified as important regulators of postnatal cardiomyocyte mitotic arrest [11]. 
Further studies demonstrate that cardiomyocyte proliferation can be inhibited by this family of miRNAs 
through the repression of multiple cell cycle regulators. Interestingly, the expression of miR-15 family 
was also shown to be up-regulated in cardiac ischemia and heart failure [12]. Recently, it has been 
reported that neonatal mammalian hearts can regenerate after myocardial infarction through the 
proliferation of preexisting cardiomyocytes, and that the miR-15 family of miRNAs participates in this 
process in neonatal hearts [13]. Furthermore, it was reported that miR-15 induces apoptosis by targeting 
anti-apoptotic factor Bcl2 [14]. Together, these studies suggest that the miR-15 family may play distinct 
roles in cardiomyocyte proliferation, apoptosis under different developmental and/or pathological 
conditions, implying their potential to treat cardiac regeneration related disease. 
Recently, an exciting breakthrough was achieved in which Ieda et al. developed a new strategy to 
directly reprogram fibroblasts into cardiomyocytes through the combination of three cardiac-specific 
transcriptional factors, Gata4, Mef2c, and Tbx5 (GMT) in vitro [15]. The above observation was further 
supported by two independent studies, in which Qian et al. and Song et al. demonstrated that 
cardiomyocyte direct reprogramming was also achievable in vivo [16,17]. These investigators reported 
that they were able to use three (GMT) or four cardiac transcription factors, Gata4, Hand2, Mef2c, and 
Tbx5 (GHMT) respectively, to reprogram cardiac fibroblasts into beating cardiomyocyte-like cells. 
More importantly, reprogramming cardiac fibroblasts into cardiomyocytes in vivo was shown to 
improve cardiac function and reduce cardiac fibrosis in a mouse model of myocardial infarction. It is not 
known whether miRNAs are involved in the process of reprogramming in these studies. However, it was 
reported in a separated study that a combination of miR-1, miR-133, miR-208, and miR-499 was able to 
directly induce the cellular reprogramming of fibroblasts into cardiomyocyte-like cells in vitro [18]. In 
this study, the investigators showed that miR-1 alone is sufficient to induce the fibroblast to cardiomyocyte 
reprogramming. However, this reprogramming efficiency was dramatically enhanced when miRNAs 
133, 208, and 499 were added. Interestingly, the process of reprogramming was further enhanced by 
about 10-fold after JAK inhibitor I treatment. Moreover, administration of miRNAs into ischemic mouse 
myocardium resulted in direct conversion of cardiac fibroblasts to cardiomyocytes in situ. Recently, 
Nam et al., used a combination of transcription factors and miRNAs to induce direct reprogramming of 
fibroblasts into cardiomyocyte-like cells [19]. They treated human fibroblasts with four transcriptional 
factors, GATA-4, Hand2, Tbx5 and Myocardin [20], together with two miRNAs, miR-1 and miR-133. A 
portion of the treated human fibroblasts was reprogrammed into cells with sarcomere-like structures, 
showing spontaneous contractility after 4 to 11 weeks in culture, suggesting the success of partial 
reprogramming. Besides phenotypic changes, the investigators found that the transcriptome of 
reprogrammed cells had also shifted toward that of cardiomyocytes. Taken together, these studies 
indicated that miRNAs could function in concert with cardiac transcriptional factors and other signaling 
pathways to synergistically enhance cardiomyocyte reprogramming. Cells 2014, 3  886 
 
 
4. miRNAs in Cardiac Hypertrophy, Remodeling and Heart Failure 
Cardiac remodeling, which is defined as an alteration in the structure (dimensions, mass, shape) of the 
heart, is one of the major responses of the heart to biomechanical stress and pathological stimuli. 
Numerous studies have demonstrated the functional involvement of many miRNAs during cardiac 
remodeling [21]. Cardiac hypertrophy is anatomically characterized as an increase in the thickness of the 
cardiac ventricular wall, owing to the enlargement of myocyte size and/or increased fibrosis. Sustained 
cardiac hypertrophy often leads to end stage heart failure. To investigate the involvement of miRNAs in 
this process, genome-wide profiling of miRNA expression has been performed and dysregulated 
miRNAs were identified during cardiac remodeling [22,23]. For instance, miR-21 was shown to 
promote cardiac fibroblast survival and the development of cardiac fibrosis by enhancing ERK-MAP 
kinase activity through the down-regulation of Sprouty homologue 1, a direct target of miR-21 and an 
endogenous inhibitor of ERK-MAP kinase [24]. Inhibition of miR-21 via an antagomir was shown to 
repress cardiac hypertrophy and fibrosis in vivo in response to stress. However, these results could not be 
verified through genetic deletion of miR-21 in mice [25], indicating that miR-21 may not be essential 
for the pathological remodeling of the heart. Most recently, it was reported that cardiac fibroblasts 
secrete star miRNA-enriched exosomes and identify fibroblast-derived miR-21* as a paracrine signaling 
mediator of cardiomyocyte hypertrophy that has potential as a therapeutic target [26]. Another study 
showed that isoproterenol-induced cardiac hypertrophy could be repressed when miR-23a was 
knocked down. miR-23a represents another miRNA up-regulated during hypertrophy and the repressive 
effect of miR-23a in cardiac hypertrophy was suggested, at least in part, due to the repression of MuRF1, 
an anti-hypertrophic factor [27]. 
Recently, we and others demonstrated that miR-22, a miRNA enriched in cardiomyocytes but only 
mildly up-regulated during cardiac hypertrophy, significantly promotes cardiac hypertrophy in vitro and 
in vivo [28,29]. Cardiac-specific knockout of miR-22 in mice repressed stress-induced cardiac 
hypertrophy, accompanied by accelerated dilation. Conversely, cardiac-specific overexpression of 
miR-22 induced spontaneous hypertrophic growth in the heart. Additional studies showed that miR-22 
represses a broad spectrum of target genes, including Sirt1, HDAC4, PPARα, and Purb, a negative 
regulator of Serum Response Factor (SRF) during the regulation of cardiac hypertrophy [28,29]. 
In another study, we demonstrated that miR-155 is expressed in cardiomyocytes and that its 
expression is reduced in pressure overload-induced hypertrophic hearts [30]. In mouse models of cardiac 
hypertrophy, genetic deletion of miR-155 suppressed cardiac hypertrophy and cardiac remodeling in 
response to pathological stressors, including both transverse aortic constriction and an activated 
calcineurin transgene. Most importantly, we found that loss of miR-155 prevented the progress of heart 
failure and substantially extended the survival of calcineurin transgenic mice. These studies uncovered 
miR-155 as an inducer of pathological cardiomyocyte hypertrophy and suggested that inhibition of 
endogenous miR-155 might have clinical potential to suppress cardiac hypertrophy and heart failure. 
Given that miR-155 is expressed in both cardiomyocytes and non-cardiomyocytes of the heart, it is 
important to define the role of this miRNA in myocyte vs. non-myocyte portions of the heart in future 
studies. Furthermore, a recent study demonstrated that paracrine regulation of cardiac miRNAs by 
transplanted bone marrow progenitor cells contributes to the anti-fibrotic effect. Mechanistically, it was Cells 2014, 3  887 
 
 
found that bone marrow progenitor cells release HGF, which inhibits miR-155-mediated profibrosis 
signaling, thereby preventing cardiac fibrosis under diabetic conditions [31]. 
Cardiac fibrosis, which is defined as abnormal deposition of collagen by cardiac fibroblasts, is often 
observed to replace the “drop-out” of cardiomyocytes during cardiac remodeling. Many genes and 
molecular pathways have been reported to participate in the regulation of this process. It is not surprising 
that miRNAs were reported to regulate cardiac fibrosis in recent years. Connective tissue growth  
factor (CTGF) is a key molecule in the process of fibrosis and therefore seemingly serves as an  
attractive therapeutic target [32]. However, it was unknown how CTGF transcripts were regulated 
post-transcriptionally. Duisters et al. showed that miR-133 and miR-30 were involved in myocardial 
matrix remodeling through regulating CTGF [33]. Both miR-133 and miR-30 were found consistently 
down-regulated in several models of heart failure and pathological hypertrophy. Knockdown of these 
miRNAs resulted in a strong increase of CTGF levels. Conversely, overexpression of miR-133 and 
miR-30c repressed the production of collagens, which was accompanied with a decrease in CTGF 
expression levels. In another study, the miR-29 family, which is predominantly expressed in cardiac 
fibroblasts [34], was found to be significantly down-regulated in the fibrotic border zone of infracted 
hearts. Intriguingly, many of the miR-29 downstream target genes, such as FBN1, COL1A1, COL1A2, 
ELN and COL3A1, are up-regulated after myocardial infarction, suggesting that miR-29 controls the 
physiological levels of many matrix proteins in such a manner that down-regulation of miR-29 is 
associated with an excessive accumulation of matrix protein and cardiac fibrosis. Though the function of 
miR-29 in cardiac fibrosis was established using gain- and loss-of function studies in vitro and in vivo, 
genetic evidence is still lacking to support the conclusion. Taken together, emerging evidences have 
demonstrated that miRNAs are not only important for cardiovascular development, but also essential 
factors for cardiac hypertrophy and remodeling. 
miRNAs also play important roles in endothelial function, vascular integrity, and angiogenesis. 
Endothelial cell-restricted miR-126 mediated developmental angiogenesis via enhancement of the 
pro-angiogenic actions of VEGF and FGF and promoted blood vessel formation by repressing the 
expression of Spred-1, an intracellular inhibitor of angiogenic signaling [35]. miR-24 is enriched in 
cardiac endothelial cells and upregulated after cardiac ischemia, and acts as a critical regulator of 
endothelial cell apoptosis and angiogenesis [36]. Furthermore, it has been reported that miR-24 
suppression prevents the transition from compensated hypertrophy to decompensated hypertrophy  
by stabilizing junctophilin-2 expression and protecting the ultrastructure of T-tubule-sarcoplasmic 
reticulum junctions [37]. Similarly, miR-210 can improve angiogenesis, inhibit apoptosis, and improve 
cardiac function in a murine model of myocardial infarction, though the molecular mechanism is not 
fully understood [38]. 
5. Cardiac Ischemia Regulated by miRNAs 
Ischemia is an independent risk factor of cardiovascular events, which leads to myocardial infarction 
and ischemia-reperfusion injury. At cellular level, cardiomyocytes often undergo apoptosis following 
myocardial infarction and ischemia-reperfusion injury. Several miRNAs participate in the regulation of 
these pathologic processes. miR-92a, a member of the miR-17-92 cluster involved in cardiomyocyte 
proliferation, also participates in the control of cardiomyocyte survival by targeting integrin subunit α5 
and eNOS. Inhibition of miR-92a by antagomir improved cardiac function and reduced cardiomyocyte Cells 2014, 3  888 
 
 
apoptosis after MI in mice [39]. miR-21 serves as an anti-apoptotic factor in myocardial infarction 
animal models by targeting PDCD4 and repressing its expression. Interestingly, miR-21 seems to target 
cardiac fibroblasts, not cardiomyocytes, in the early phase of acute myocardial infarction, highlighting 
the significant contribution of cardiomyocyte-fibroblast interaction to cardiac function [40]. Conversely, 
miR-320 is down-regulated after ischemia-reperfusion injury. Gain- and loss-of-function studies 
demonstrated that miR-320 promotes cardiomyocyte apoptosis via maintaining HSP20 levels [41]. It is 
speculated that additional miRNAs will be found participating in the regulation of cardiac ischemia and 
heart disease. 
6. miRNAs “Conducting” Arrhythmia  
The cardiac conduction system can be damaged following cardiac injury, such as cardiac ischemia or 
acute MI, and cellular necrosis can lead the dysfunction of the whole cardiac conduction system, 
including the sinoatrial node, atrioventricular node, and His-Purkinje system. Electrical signals cannot 
be conducted smoothly through this damaged conduction system, resulting in a series of arrhythmia. 
miRNAs have been shown to participate in this process and the proper expression of miRNAs is critical 
for sustaining the normal function of cardiac conduction system. For instance, it has been reported that 
miR-1 and miR-133, two most commonly expressed miRNAs in striated muscle, target several ion 
channel and gap-junction associated genes, such as HCN2, HCN4, KCNJ2, ERG and GJA1 (Cx43) [42]. 
Overexpression of miR-1 in infarcted myocardium can promote arrhythmogenesis, whereas arrhythmia 
could be alleviated through deleting endogenous miR-1. miR-208a, a cardiac-specific miRNA encoded 
by the intron of the myosin heavy chain gene Myh6, has also been demonstrated to play an important 
role in arrhythmogenesis [43], especially in the process of atrial depolarization, by regulating the 
expression of Connexin-40 (GJA5). Therefore, studies have established the role of miRNAs in the 
development and maintenance of the cardiac conduction system. 
7. Diagnostic and Therapeutic Uses of miRNAs 
miRNAs could be utilized as biomarkers for the diagnosis of cardiovascular disease, given that the 
expression of many miRNAs is altered in a variety of cardiac biologic processes and disease conditions. 
Importantly, “circulating miRNAs” appear to be stable in mammalian serum and plasma, which are easy 
to acquire, raising the possibility that they could serve as biomarkers for heart disease diagnosis and 
prediction [44,45]. Recently, a clinical study has already made progress toward this possibility by 
showing that circulating miR-192 levels are correlated with the development of ischemic heart failure 
after acute myocardial infarction in human patients [46]. Furthermore, it has been reported that several 
circulating miRNAs, such as miR-133, miR-1291, miR-663b, miR-328, and miR-134, exhibit clinical 
impact on human myocardial infarction [47,48]. Likewise, miR-328 can be a potential mediator of 
atrial remodeling and atrial fibrillation [49]. 
Though the therapeutic potential of miRNAs in cardiovascular disease remains debatable, much 
remarkable progress in miRNA-based translational medicine has been made. Cardiologists are now 
attempting to use miRNAs and/or their inhibitors to treat heart diseases. In addition, many efficient 
techniques to manipulate miRNA levels in vivo have been developed. Among these techniques, 
antagomirs, which knock down targeted miRNAs by sequestering them from the functional complex, Cells 2014, 3  889 
 
 
were shown to be stable in blood [50]. Conversely, miRNA mimics, synthesized chemically modified 
double-stranded oligonucleotides, can create gain-of-function effects for specific miRNAs in vitro and 
in vivo [51,52]. With the identification of miRNAs and their targets in normal and diseased hearts and 
the understanding of their function (Table 1), we are confident that diagnostic tools and therapeutics 
based on miRNAs will play even more important roles in the field of cardiology. 
Table 1. miRNAs and their targets implicated in the function of the heart. 
microRNA miRNA  Targets  Function  in the Heart  Reference(s) 
miR-1  RhoA, Cdc42, Nelf-A/WHSC2,   
Kcnj2, Gja1, Ppp2r5a, Vegfa 
cardiac hypertrophy, arrythmia, reprogramming 
of fibroblasts into cardiomyocyte-like cells 
[18,42,53,54] 
miR-15 Chek1  postnatal  cardiomyocyte mitotic arrest  [11] 
miR-16 Chek1  postnatal  cardiomyocyte mitotic arrest  [11] 
miR-19 Pten  cardiomyocyte  proliferation  [10] 
miR-21  Ppara, Mpv17l, Sorbs2, Pdlim5, PDCD4  ischemia/reperfusion, cardiac hypertrophy [24,25,40] 
miR-22 Sirt1,  HDAC4,  PPARα, Purb  cardiac hypertrophy  [28,29] 
miR-23 MuRF1  cardiac  hypertrophy  [27] 
miR-25  Serca2, Ip3r1  arrythmia, heart failure  [55] 
miR-26 KCNJ2    arrythmia  [56] 
miR-29  Col1a1, Col1a2, Col3a1, ELN  arrythmia, cardiac fibrosis  [34] 
miR-30 CTGF  cardiac  fibrosis  [33] 
miR-34  PPP1R10, vinculin, Sema4b, Pofut1, Bcl6 myocardial infarction, cardiac hypertrophy  [57,58] 
miR-132 FoxO3  cardiac  hypertrophy  [59] 
miR-133 CTGF  cardiac  fibrosis,  cardiac hypertrophy, cardiac 
remodeling, reprogramming of fibroblasts into 
cardiomyocyte-like cells 
[18,33,47,54] 
miR-155  Jarid2, Socs1  cardiac hypertrophy, cardiac fibrosis  [30,31] 
miR-195 Chek1  postnatal  cardiomyocyte mitotic arrest  [11] 
miR-199  Dyrk1a    cardiac hypertrophy, cardiomyocyte 
proliferation 
[9] 
miR-208  Med13  cardiac hypertrophy, reprogramming of 
fibroblasts into cardiomyocyte-like cells 
[18] 
miR-212 FoxO3  cardiac  hypertrophy  [59] 
miR-214  Slc8a1, Bcl2l11, Ppif cardiac  remodeling  [60] 
miR-320 Hsp6b  myocardial  ischemia  [41] 
miR-328 Cacna1c,  Cacnb1  atrial fibrillation  [61] 
miR-486  Pten, Foxo1a  cardiac hypertrophy  [62] 
miR-497 Chek1  postnatal  cardiomyocyte mitotic arrest  [11] 
miR-499  Calcineurin, Drp1  cardiac hypertrophy, reprogramming of 
fibroblasts into cardiomyocyte-like cells 
[18,63] 
miR-590 unknown  cardiomyocyte  proliferation  [9] 
8. Long Non-Coding RNAs (LncRNAs) in Cardiac Development 
Long ncRNAs (lncRNAs) are a novel class of ncRNAs that are larger than 200 nucleotides but do not 
encode proteins. Thousands of lncRNAs have been identified in different species. Emerging evidence 
has suggested that lncRNAs have crucial roles in controlling gene expression and other cellular Cells 2014, 3  890 
 
 
processes during both developmental and differentiation processes. lncRNAs regulate gene expression 
at the levels of epigenetic control, transcription, RNA processing, and translation. Many lncRNAs have 
recently been discovered and their function in a variety of biological processes is emerging. However, 
relatively little is known about the involvement of lncRNAs in the cardiovascular system. A novel 
lncRNA, Braveheart, has been identified as a critical regulator of cardiovascular commitment from 
embryonic stem cells [64,65]. Braveheart activates a cardiovascular gene network and functions 
upstream of mesoderm posterior basic helix-loop-helix transcription factor 1 (MESP1), a master 
regulator of a common multi-potent cardiovascular progenitor. Braveheart mediates the epigenetic 
regulation of cardiac commitment by interacting with SUZ12, a component of the polycomb repressive 
complex 2 (PRC2), which appears to be a common mechanism for lncRNAs’ function. Braveheart 
therefore represents the first lncRNA that defines cardiac cell fate and lineage specificity, linking 
lncRNAs to cardiac development and disease. However, it remains to be seen if Braveheart is required 
for normal heart development in vivo. Braveheart appears to exist as a mouse specific lncRNA, as direct 
sequence alignment did not identify mouse Braveheart homologues in other species. The expression of 
Braveheart was nicely documented in mouse ESCs and heart samples using an RNA-Seq approach. 
However, the potentially orthologous human and rat genomic regions were not actively transcribed. The 
lack of an apparent human Braveheart homologue raises the question of how well the lessons learned 
from mouse Braveheart will translate to human cardiovascular disease. Perhaps an undiscovered 
functional Braveheart homologue, transcribed from a different genomic locus, exists in the human 
genome. Nevertheless, the discovery of Braveheart will likely impact the cardiovascular research field. 
Fendrr, another novel lncRNA expressed in the heart, is one of very few lncRNAs whose in vivo 
functions have been explored using mouse genetics. Two independent studies demonstrated that loss of 
Fendrr is lethal in mice. Mutant mice display a spectrum of defects, including cardiac morphogenesis, 
consistent with the findings that Fendrr is expressed in the mouse lateral plate mesoderm and developing 
hearts [66,67]. However, there is a difference in the phenotype severity associated with the two mutant 
mouse lines; while one mutant line dies embryonically around E13.75, the other one dies postnatally. 
One possible explanation for this discrepancy is the different targeting strategies used to remove the 
Fendrr gene. Mechanistically, Fendrr was shown, similarly to Braveheart, to interact with the PRC2 
complex to modulate the epigenetic regulation of gene expression. In addition, Fendrr may be involved 
in the control of the activating H3K4me3 mark on a subset of promoters, thereby modifying the 
expression level of those genes. However, the mechanisms of Fendrr-dependent molecular events 
remain to be fully understood. It is expected that many more lncRNAs will be found to play important 
roles in cardiovascular development and function. 
9. lncRNAs in Cardiac Disease 
Given the emerging role of lncRNAs in a large spectrum of biological systems examined, it is not 
surprising that several recent studies have identified many lncRNAs associated with diseased hearts, 
both in human patients with cardiovascular disease and mouse models for human disease. In these 
studies, the investigators took genome-wide, next generation RNA sequencing approaches and documented 
many lncRNAs expressed in the heart. Most importantly, they found that expression of cardiac-expressed or 
circulating lncRNAs was altered in patients with cardiomyopathy or heart failure [68–71]. Future Cells 2014, 3  891 
 
 
investigations will certainly link the functional characteristics of lncRNAs to maladaptive remodeling, 
cardiac function, cardiac regeneration and cardiovascular disease. 
Recent studies also linked several lncRNAs to heart disease. ANRIL, an lncRNA, was identified as a 
risk factor for coronary disease [72]. Though it is still not fully understood how ANRIL functions, 
evidence suggests that this lncRNA may participate in the regulation of histone methylation [73]. 
Another lncRNA, MIAT (myocardial infarction-associated transcript) (or Gomafu/RNCR2) was 
identified as a risk factor associated with patients with myocardial infarction [74]. However, how MIAT 
controls the status of myocardial infarction remains largely unknown. Intriguingly, the genetic loci that 
encode MYH6 and MYH7, the main myosin heavy chain genes in cardiac muscle, appear to produce a 
non-coding anti-sense transcript (Myh7-as). Myh7-as transcription may regulate the ratio of Myh6 and 
Myh7, altering the function of muscle contraction [75]. 
While  Braveheart was shown to be an important lncRNA for cardiac cell fate, additional 
cardiac-expressed lncRNAs, in particular those selectively expressed in cardiomyocytes, remain to be 
identified and studied. Intriguingly, recent studies demonstrate that cardiac transcription factors and 
miRNAs reprogram cardiac fibroblasts into cardiomyocytes in vitro and in vivo [15–18], raising the 
tantalizing possibility that reprogramming strategies may be used to enhance the limited native 
regenerative capacity of adult mammalian hearts [76,77]. Most recently, one novel lncRNA, 
lincRNA-RoR, was reported to modulate the reprogramming of induced pluripotent stem cells, at least 
in part, by regulating the expression levels and activities of key reprogramming factors, Oct4, Sox2, and 
Nanog [78]. These studies suggest that lncRNAs could form a feedback loop with core TFs and miRNAs 
to regulate ESC maintenance and differentiation. It will be interesting to determine whether lncRNAs 
might also participate in cardiac regeneration or be used to stimulate cellular reprogramming to directly 
reprogram non-myocyte cells such as cardiac fibroblasts into cardiomyocytes. 
10. lncRNAs as Competing Endogenous RNA 
Recently, it has been reported that competing endogenous RNAs (ceRNAs) regulate the distribution 
of miRNA molecules on their targets and thereby impose an additional level of post-transcriptional 
regulation. In particular, a muscle-specific lncRNA, linc-MD1, sponges miR-133 to regulate the 
expression of MAML1 and MEF2C, transcription factors that activate muscle-specific gene expression. 
It was found that HuR, which is under the repressive control of miR-133, is derepressed due to the 
sponging activity of linc-MD1 on miR-133. This study therefore uncovered a feedforward positive loop 
involving muscle transcription factors, RNA binding proteins, miRNAs, and an lncRNA, that controls 
early phases of myogenesis [79]. Interestingly, the levels of linc-MD1 are strongly reduced in muscle 
cells of patients with Duchenne Muscular Dystrophy [80]. In another study, it was reported that cardiac 
apoptosis-related lncRNA (CARL) could act as an endogenous miR-539 sponge to regulate PHB2 
expression, mitochondrial fission and apoptosis. Modulation of their levels may provide a new approach 
for tackling apoptosis and myocardial infarction [81]. Clearly, understanding this novel RNA crosstalk 
will lead to significant insight into gene regulatory networks and have implications in human 
development and disease. 
Importantly, lncRNAs have unique functional and regulatory characteristics. One major finding of 
numerous recent studies of lncRNAs, specifically within the heart, was that lncRNAs are highly 
tissue-specific. Genome-wide profiling of the cardiac transcriptome after myocardial infarction Cells 2014, 3  892 
 
 
revealed hundreds of novel heart-specific lncRNAs with unique regulatory and functional characteristics 
relevant to maladaptive remodelling, cardiac function, and possibly cardiac regeneration [68]. This 
finding implies that heart-specific lncRNAs have ample possibilities as targeting molecules and 
biomarkers relevant to cardiac development and disease.  
11. Future Prospects 
We have just started the era of “non-coding”. We are looking forward to see more and more reports 
on the roles of non-coding RNAs (miRNAs and lncRNAs) in the regulation of a variety of essential 
biological processes, including cardiovascular biology and disease. It is an exciting time to investigate 
the function of non-coding RNAs, and advanced technology development will certainly propel the 
research field forward. Many efficient techniques to manipulate miRNA levels in vitro and in vivo, 
such as antagomirs and miRNA mimics, have been developed for loss- and gain-of-function studies. 
Additionally, the rAAV9 vector has been demonstrated to have high affinity for myocardium [82], 
providing a powerful tool for delivering miRNA- and lncRNA-related therapeutic molecules 
specifically to the heart through intravenous injections.  With efficient strategies for gain- and 
loss-of-function investigations, more fruitful work about the molecular mechanism and therapeutic 
application of non-coding RNAs in cardiovascular disease will emerge. We are confident that 
non-coding RNAs will take the central stage of cardiovascular medicine in the foreseeable future. 
Non-coding RNAs represent potential therapeutic targets for cardiac disease as well as attractive 
candidate biomarkers to be used in the clinic. 
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